Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma

Area of Science:

• Neuro-oncology
• Genomics
• Cancer Biology

Background:

• Prognostic and therapeutic challenges persist in diffuse gliomas.
• Clonal architecture of mutations remains underexplored in glioma prognosis.

Purpose of the Study:

• To develop an integrative framework for inferring mutation clonal status in glioblastoma (GBM) and low-grade glioma (LGG).
• To systematically investigate the prognostic value of clonal and subclonal mutations in GBM and LGG.
• To explore the genomic features and regulatory mechanisms associated with high-risk subclonal mutations.

Main Methods:

• Utilized exome sequencing data from The Cancer Genome Atlas (TCGA).
• Developed an integrative framework to infer clonal status of mutations.
• Analyzed associations between subclonal mutations, genomic instability, intratumor heterogeneity, and patient survival.

Main Results:

• Most mutant genes exhibited both clonal and subclonal mutations.
• Subclonal mutations were more strongly associated with poor prognosis than clonal mutations.
• Risk subclonal mutations linked to genomic instability and intratumor heterogeneity.
• Specific subclonal mutations (e.g., AHNAK, AHNAK2, NF1, PTEN) identified as potentially influencing glioma progression.
• Advanced subclonal mutations correlated with poorer overall survival.

Conclusions:

• Clonal status is critical for accurate glioma prognosis analysis.
• Subclonal mutations play a significant, often underestimated, role in glioma prognosis and tumor evolution.
• Identifying risk subclonal mutations offers potential therapeutic and prognostic insights.